학술논문

A Mouse-Adapted SARS-CoV-2 Induces Acute Lung Injury and Mortality in Standard Laboratory Mice
Document Type
Report
Source
Cell. Nov 12, 2020, Vol. 183 Issue 4, 1070
Subject
Standards
Analysis
Health aspects
Surface active agents -- Analysis
Surface active agents -- Health aspects
Biological response modifiers -- Analysis
Biological response modifiers -- Health aspects
House mouse -- Analysis
House mouse -- Health aspects
COVID-19 -- Analysis
COVID-19 -- Health aspects
Interferon -- Standards
Epidemiology -- Analysis
Epidemiology -- Health aspects
Adult respiratory distress syndrome -- Health aspects
Adult respiratory distress syndrome -- Analysis
Acute respiratory distress syndrome -- Health aspects
Acute respiratory distress syndrome -- Analysis
Mice -- Analysis
Mice -- Health aspects
Language
English
ISSN
0092-8674
Abstract
Keywords SARS-CoV-2; COVID-19; animal models; mouse-adaptation; acute lung injury; acute respiratory distress syndrome; interferon; vaccines Highlights * Serial in vivo evolution selected for a lethal mouse-adapted SARS-CoV-2 MA10 variant * SARS-CoV-2 MA10 shows a dose- and age-related increase in pathogenesis in BALB/c mice * Mice exhibit ALI, ARDS, and surfactant loss, key metrics in countermeasure performance * SARS-CoV-2 MA10 model enables access to immune reagents and genetically defined mice Summary The SARS-CoV-2 pandemic has caused extreme human suffering and economic harm. We generated and characterized a new mouse-adapted SARS-CoV-2 virus that captures multiple aspects of severe COVID-19 disease in standard laboratory mice. This SARS-CoV-2 model exhibits the spectrum of morbidity and mortality of COVID-19 disease as well as aspects of host genetics, age, cellular tropisms, elevated Th1 cytokines, and loss of surfactant expression and pulmonary function linked to pathological features of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). This model can rapidly access existing mouse resources to elucidate the role of host genetics, underlying molecular mechanisms governing SARS-CoV-2 pathogenesis, and the protective or pathogenic immune responses related to disease severity. The model promises to provide a robust platform for studies of ALI and ARDS to evaluate vaccine and antiviral drug performance, including in the most vulnerable populations (i.e., the aged) using standard laboratory mice.